3 results
Approved WMORecruiting
The primary objective is to determine if the addition of daratumumab to VRd will prolong PFS defined as the time from the date of randomization to the date of disease progression (assessed by International Myeloma Working Group [IMWG] criteria) or…
Approved WMORecruiting
The aim is to see whether intradialytic parenteral nutrition is an efective treatment against the loss of muscle mass
Approved WMORecruiting
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.